CDIO vs REGN: Which Stock is Better?
Side-by-side comparison of Cardio Diagnostics Holdings Inc and Regeneron Pharmaceuticals Inc in 2026
CDIO
Cardio Diagnostics Holdings Inc
$2.01
REGN
Regeneron Pharmaceuticals Inc
$750.57
Key Metrics Comparison
| Metric | CDIO | REGN | Winner |
|---|---|---|---|
| Market Cap | $5.95M | $79.35B | REGN |
| P/E Ratio | N/A | 18.08 | REGN |
| EPS (TTM) | $N/A | $41.51 | REGN |
| Revenue Growth | -0.2% | 0.0% | REGN |
| Gross Margin | 100.0% | 44.6% | CDIO |
Analyze CDIO
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CDIO or REGN a better investment?
Comparing CDIO and REGN: Cardio Diagnostics Holdings Inc has a market cap of $5.95M while Regeneron Pharmaceuticals Inc has $79.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CDIO and REGN?
CDIO (Cardio Diagnostics Holdings Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CDIO or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CDIO or REGN?
REGN has higher revenue growth at 0.0% vs -0.2% for CDIO.
Which company is more profitable: CDIO or REGN?
Cardio Diagnostics Holdings Inc (CDIO) has higher gross margins at 100.0% compared to 44.6% for REGN.
Which is the larger company: CDIO or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.35B compared to $5.95M for CDIO.
Should I buy CDIO or REGN in 2026?
Both CDIO and REGN have investment merit. CDIO trades at $2.01 while REGN trades at $750.57. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CDIO and REGN stock?
Key differences: Market Cap ($5.95M vs $79.35B), P/E Ratio (N/A vs 18.1x), Revenue Growth (-0.2% vs 0.0%), Gross Margin (100.0% vs 44.6%).